Esophageal Adenocarcinoma — Variants & evidence

Esophageal Adenocarcinoma — Variants & evidence · CancerIndex

Variants & evidence

Curated clinical evidence by variant and therapy

3 evidence items mapped to this entity or its descendants, grouped by molecular profile, then therapy. 50 items per page.

civicCuratedShowing 1–3 of 3 evidence items (1 on this page mapped to a descendant entity) · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
AURKA Amplification1
Alisertib + CisplatinCombination	Esophageal AdenocarcinomaALIAS	Predictive	E	Supports Sensitivity Response	3	accepted	EID456 Antitumour effect of alisertib treatment in esophageal adenocarcinomas can be intensified in combination with cisplatin. PMID 22302096 · Sehdev et al., 2012 · Open in CIViC	civic
AURKA Overexpression1
Alisertib + CisplatinCombination	Esophageal AdenocarcinomaALIAS	Predictive	D	Supports Sensitivity Response	4	submitted	EID9627 The efficacy of novel AURKA inhibitor alisertib (MLN8327) was tested alone or in combination with cisplatin in three esophageal adenocarcinoma cell lines (FLO-1, OE19 and OE33) that overexpress AURKA.… (full text at CIViC) PMID 22302096 · Sehdev et al., 2012 · Open in CIViC	civic
EGFR Amplification1
(prognostic)	Barrett AdenocarcinomaALIAS	Prognostic	B	Supports Poor Outcome	3	accepted	EID470 In patients with Barrett's adenocarcinoma, those with amplification of EGFR had shorter disease-specific survial. PMID 20840671 · Marx et al., 2010 · Open in CIViC	civic

Data updated 23 hours agoSource updated unknownsource: civic (CC0)

Evidence levels, directions and ratings are those assigned by CIViC curators. "Submitted" items have not completed curation review. This is not treatment guidance.